Company Statements

07/02/2021

Gilead Sciences Response to Open Letter Regarding Access to AmBisome® (liposomal amphotericin B)

04/21/2021

Gilead Statement on New England Journal of Medicine Publication of Positive Phase 3 ASCENT Study of Trodelvy in Metastatic Triple-Negative Breast Cancer

04/12/2021

Gilead Sciences Statement on Phase 3 Veklury® (Remdesivir) Intravenous Study in High Risk Non-Hospitalized Patients with COVID-19

04/09/2021

Gilead Announces Additional Updates to The Advancing ACCESS® Patient Assistance/Medication Assistance Program

04/08/2021

Gilead Announces Updates to The Advancing ACCESS® Patient Assistance/Medication Assistance Program

02/09/2021

Gilead Announces Plans for New Location in North Carolina’s Research Triangle Region Dedicated to Business Services

02/07/2021

Gilead Sciences Statement on the Passing of the Honorable George P. Shultz, PhD

01/13/2021

Gilead Sciences Statement on Recent Events in Washington, D.C.

12/21/2020

Gilead Announces New Arm of HIV Women’s Prevention Study to Evaluate the Investigational Long-Acting HIV-1 Capsid Inhibitor Lenacapavir in Addition to Descovy for PrEP®

11/19/2020

Gilead Sciences Statement on The World Health Organization’s Updated Veklury® (Remdesivir) COVID-19 Treatment Guidelines

10/15/2020

Gilead Sciences Statement on the Solidarity Trial

09/23/2020

Statement from Brett Pletcher on Gilead Sciences Settlement Over Charitable Donations

09/23/2020

Gilead Remains Committed to Maintaining Advancing Access® Program for HIV Prevention and Treatment Medicines

08/06/2020

Gilead Sciences Update on Veklury® (Remdesivir) Manufacturing Network

08/05/2020

Gilead Sciences Statement on State Attorneys General Letter on Remdesivir

07/08/2020

Gilead Sciences Statement on the Initiation of Clinical Testing of an Inhaled Solution of Remdesivir for Potential Outpatient Treatment of COVID-19

06/17/2020

Gilead Sciences Statement on Phase 2/3 Clinical Trial of Remdesivir in Pediatric Patients Hospitalized With COVID-19

06/01/2020

Gilead Sciences Statement on Remdesivir Clinical Data

05/29/2020

Gilead Sciences Response to U.S. Senators on Trial Diversity

05/22/2020

Gilead Sciences Statement on NEJM Publication of Remdesivir Data From NIAID Study

05/05/2020

Gilead Sciences Statement on Expanding Global Supply of Investigational Antiviral Remdesivir

04/24/2020

Gilead Statement on Complaint Against Federal Government in The Court of Federal Claims

04/23/2020

Gilead Sciences Statement on Data From Remdesivir Study in Patients With Severe COVID-19 in China

04/10/2020

Gilead Sciences Response to Médecins Sans Frontières

03/25/2020

Gilead Sciences Statement on Request to Rescind Remdesivir Orphan Drug Designation

03/23/2020

Gilead Sciences Statement on Ensuring Continued  Supply of HIV Medicine Amid Coronavirus Outbreak

03/22/2020

Gilead Sciences Statement on Access to Remdesivir Outside of Clinical Trials

02/05/2020

Gilead Statement on U.S. Patent and Trademark Office Decision to Deny Request for Inter Partes Review of HIV PrEP Patents

01/31/2020

Gilead Sciences Statement on the Company’s Ongoing Response to the 2019 Novel Coronavirus (2019-nCoV)

12/03/2019

Gilead Statement on Commitment to Advancing Descovy for PrEP™ Study in Cisgender Women & Adolescent Females

11/07/2019

Gilead Statement on U.S. Government Complaint Regarding HIV PrEP and PEP Patents

08/21/2019

Petitions to US Patent and Trademark Office on HIV PrEP Patents

06/11/2019

Gilead Sciences Statement on U.S. Preventive Services Task Force 'A' Recommendation for PrEP as an HIV Prevention Strategy

05/14/2019

Gilead Sciences Statement On Inaccurate Reporting On Truvada®

04/10/2019

Gilead Sciences Statement on Commitment to Providing Price Information

04/04/2019

Gilead Sciences Commits to Reducing our Global Greenhouse Gas Emissions by 25 Percent by 2025

04/03/2019

Gilead Sciences Announces $500,000 Grant To Pan American Development Foundation To Provide Emergency Health Services For Venezuelan Migrants And Host Communities In Colombia

09/27/2018

Gilead Sciences Statement on Grants to Spouses of Caricom Leaders Action Network (SCLAN) to Expand Access to Youth HIV Prevention and Care in the Caribbean

09/24/2018

A perspective from our CEO: Gilead Subsidiary to Launch Authorized Generics to Treat HCV

09/07/2018

Gilead Sciences Announces Steep Discounts for Ambisome to Treat Cryptococcal Meningitis in Low- and Middle-Income Countries

05/02/2018

Gilead Publishes 2017 Year in Review

11/09/2017

Gilead Sciences Announces 100 Percent Score on 2018 Human Rights Campaign Corporate Equality Index

09/01/2017

Gilead Implements Emergency Disaster Response Procedures to Ensure Medicine Access

05/01/2017

Gilead Publishes Year in Review 2016

12/06/2016

Gilead Recognized as Top Corporate Philanthropist in Funders Concerned About AIDS Report

12/01/2016

Gilead HIV Medicines Now Reaching 10 Million People in Developing Countries

11/11/2016

Statement on DISCOVER Study of F/TAF for PrEP

08/01/2016

Gilead Publishes 2015 Corporate Social Responsibility Report

08/14/2015

Gilead Supports PrEP Education to Increase HIV Prevention and Awareness

08/12/2015

Gilead Publishes Its 2014 Corporate Contributions Report